Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Short-term Investments (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Short-term Investments for 14 consecutive years, with $148.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 24309.87% year-over-year to $148.4 million, compared with a TTM value of $148.4 million through Dec 2025, up 24309.87%, and an annual FY2025 reading of $156.6 million, down 25.78% over the prior year.
  • Short-term Investments was $148.4 million for Q4 2025 at Enanta Pharmaceuticals, down from $156.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $298.8 million in Q1 2021 and bottomed at $608000.0 in Q4 2024.
  • Average Short-term Investments over 5 years is $195.0 million, with a median of $194.3 million recorded in 2024.
  • The sharpest move saw Short-term Investments plummeted 99.8% in 2024, then soared 24309.87% in 2025.
  • Year by year, Short-term Investments stood at $160.0 million in 2021, then increased by 7.67% to $172.2 million in 2022, then surged by 72.55% to $297.2 million in 2023, then tumbled by 99.8% to $608000.0 in 2024, then skyrocketed by 24309.87% to $148.4 million in 2025.
  • Business Quant data shows Short-term Investments for ENTA at $148.4 million in Q4 2025, $156.6 million in Q3 2025, and $159.3 million in Q2 2025.